Get to know our clinical trials
Open-label clinical trial of E7386 in combination with other anticancer drugs in subjects with solid tumors.
THE PRIMARY OBJECTIVE OF THIS STUDY IS TO EVALUATE THE SAFETY AND TOLERABILITY AND DETERMINE THE RECOMMENDED PHASE 2 DOSE (RP2D) OF E7386 IN COMBINATION WITH OTHER ANTICANCER DRUG(S), AND TO DETERMINE THE OPTIMAL DOSE OF E7386 IN COMBINATION WITH LENVATINIB IN ENDOMETRIAL CARCINOMA (EC) (ONLY FOR THE EC DOSE OPTIMIZATION PORTION).
Technical Summary
- OPEN-LABEL STUDY OF E7386 IN COMBINATION WITH OTHER ANTICANCER DRUGS IN SUBJECTS WITH SOLID TUMORS.
- Code EudraCT: 2022-003300-32
- Protocol number: E7386-J081-102
- Promoter: Eisai Inc.
- Molecule/Drug: E7386
- Link to Clinical Trials
* The trials only admit a limited number of patients and are subject to inclusion and exclusion criteria. The specialist who assesses your case will inform you of the conditions required to participate in the clinical trial.
Do you want to participate in this trial?
Request an appointment for our specialists to assess whether you qualify for this clinical trial
Do you prefer to send us your reports?
If you prefer, you can send us your medical information and our specialists will evaluate your case without the need to come to the Clinica.